Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M. Palumbo A, et al. Among authors: meloni g. Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1. Blood. 2010. PMID: 19965659 Free article. Clinical Trial.
Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, De Felice L, Rusignuolo A, Simone F, Meloni G, Mandelli F. Petrucci MT, et al. Among authors: meloni g. Acta Haematol. 2003;109(4):184-8. doi: 10.1159/000070967. Acta Haematol. 2003. PMID: 12853690
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A; GIMEMA Acute Leukemia Working Party. Gregorj C, et al. Among authors: meloni g. Blood. 2007 Jun 15;109(12):5473-6. doi: 10.1182/blood-2006-05-021071. Epub 2007 Mar 9. Blood. 2007. PMID: 17351113 Free article.
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.
Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foà R, Baccarani M, Mandelli F. Vignetti M, et al. Among authors: meloni g. Blood. 2007 May 1;109(9):3676-8. doi: 10.1182/blood-2006-10-052746. Epub 2007 Jan 9. Blood. 2007. PMID: 17213285 Free article. Clinical Trial.
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. Visani G, et al. Among authors: meloni g. Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3. Blood. 2011. PMID: 21816830 Free article. Clinical Trial.
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C, Yaniv I, Fagioli F, Castel V, Shaw PJ, Ferrant A, Pession A, Sociè G, Frassoni F; European Blood and Marrow Transplantation Acute Leukemia Working Party. Locatelli F, et al. Among authors: meloni g. Blood. 2003 Feb 15;101(4):1611-9. doi: 10.1182/blood-2002-03-0764. Epub 2002 Oct 10. Blood. 2003. PMID: 12393725 Free article.
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A. Visani G, et al. Among authors: meloni g. Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. Blood. 2014. PMID: 25377565 Free article. Clinical Trial. No abstract available.
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).
Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, Chiarini F, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M. Amadori S, et al. Among authors: meloni g. Br J Haematol. 2012 Jan;156(2):205-12. doi: 10.1111/j.1365-2141.2011.08940.x. Epub 2011 Nov 15. Br J Haematol. 2012. PMID: 22082314 Free article. Clinical Trial.
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. Martelli M, et al. Among authors: meloni g. J Clin Oncol. 2003 Apr 1;21(7):1255-62. doi: 10.1200/JCO.2003.01.117. J Clin Oncol. 2003. PMID: 12663712 Clinical Trial.
643 results